-
Beijing · April 24–25 | 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (AOT 2026) to Convene
In order to comprehensively advance public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become pivotal forces in overcoming critical health challenges. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (Art of Transplant: Beijing Hematopoietic Stem Cell Transplantation Symposium, AOT 2026),…
-
Voice of China at EBMT 2026 | Professor Erlie Jiang / Dr. Xiaoyu Zhang: Exploring the Role of Third-Generation TKIs in Transplantation for Blast-Phase CML
From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential academic events in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
-
Professor Haixia Fu: Applications and Advances of TPO Receptor Agonists and ATRA in the Treatment of ITP
From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis, hosted by the Hematologic Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology, was successfully held in Beijing. The meeting brought together leading international and domestic experts, clinicians, and industry…
-
Breaking Mechanistic Barriers, Advancing Therapeutics — Professor Zeping Zhou on New Developments and Long-Term Management Strategies in ITP
Immune thrombocytopenia (ITP) is a complex autoimmune disorder involving multiple immune pathways and abnormalities in platelet production. In recent years, continuous advances in drug development and evolving treatment paradigms have been reshaping the clinical landscape of ITP.
-
Professor Heyu Ni: Interactions Between Platelets and the Immune System and Their Significance in Immune-Mediated Thrombocytopenia
From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis and the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology was successfully held in Beijing. The event brought together leading scholars, clinicians, and industry experts from around the world to exchange insights on cutting-edge developments in thrombosis and hemostasis, hematologic…
-
Annual Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care
Thrombotic diseases are associated with high incidence, mortality, and disability rates, posing a serious threat to public health. Venous thromboembolism (VTE), in particular, often presents insidiously, and dislodged thrombi can lead to pulmonary embolism—earning it the reputation of a “silent killer.”
-
Expert Interview | Prof. Shilpa Gupta Decodes Urothelial Carcinoma In-Depth: China’s Strength, Global Collaboration and Future Breakthroughs in the ADC Era
In recent years, the rapid advancement of antibody-drug conjugates (ADCs) has completely reshaped the treatment paradigm across the entire disease course of urothelial carcinoma. Meanwhile, Chinese investigators and domestically developed innovative agents have gained ever-increasing influence in the global oncology landscape. Recently, we had the exclusive opportunity to interview Prof. Shilpa Gupta, a world-leading expert…
-
Overcoming Antigen Escape: CD19/CD84 “If-Better” Dual CAR-T Cells Demonstrate Superior Control in CD19-Low B-ALL
At the recent EBMT 2026 Annual Meeting, Prof. Ane Altuna Mongelos from Hospital Clínic de Barcelona and IDIBAPS delivered a presentation titled “CD19/CD84 IF-BETTER dual CAR T cells demonstrate superior control of CD19-low B-ALL than single CAR19.” The report explored novel pathways to overcome antigen escape in B-cell acute lymphoblastic leukemia (B-ALL) through a dual-targeting…
Connecting Medical Expertise through Media